Citations

Clear

2117 citation(s) found for "Mayo, Steven".

Administration of Repeat Intravitreal Anti-VEGF Drugs by Retina Specialists in an Injection-only Clinic for Patients with Exudative AMD: Patient Acceptance and Safety
Engman, Steven J., Edwards, Albert O., Bakri, Sophie J.

Mayo Clinic

Seminars in Ophthalmology | November 1, 2011 | Volume: 26 | Issue: 6 | Pages: 380-386

10.3109/08820538.2011.622337 | PMID 22044336 Get It

Resident and Program Director Gender Distribution by Specialty
Long, Timothy R. , Elliott, Beth A., Warner, Mary E. , Brown, Michael , Rose, Steven H.

Mayo Clinic

Journal of Women's Health | October 21, 2011 | Volume: 20 | Issue: 12 | Pages: 1867-1870

10.1089/jwh.2011.2906 | PMID 22017355 Get It

Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis
Cazanave, Sophie C. , Fingas, Christian D., Guicciardi, Maria Eugenia , Bronk, Steven F., Werneburg, Nathan W., Mott, Justin L. , Kakisaka, Keisuke , Gores, Gregory J.

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | October 13, 2011 | Volume: 302 | Issue: 1 | Pages: G77-G84

10.1152/ajpgi.00301.2011 | PMID 21995961 Get It

Isolated hepatocytes undergo lipoapoptosis, a feature of hepatic lipotoxicity, on treatment with saturated free fatty acids (FFA) such as palmitate (PA). However, it is unknown if palmitate is directly toxic to hepatocytes or if its toxicity is indirect via the generation of lipid metabolites such as lysophosphatidylcholine (LPC). PA-mediated hepatocyte lipoapoptosis is associated with endoplasmic reticulum (ER) stress, c-Jun NH 2 -terminal kinase (JNK) activation, and a JNK-dependent upregulation of the potent proapoptotic BH3-only protein PUMA (p53 upregulated modulator of apoptosis). Our aim was to determine which of these mechanisms of lipotoxicity are activated by PA-derived LPC. We employed Huh-7 cells and isolated murine and human primary hepatocytes. Intracellular LPC concentrations increase linearly as a function of the exogenous, extracellular PA, stearate, or LPC concentration. Incubation of Huh-7 cells or primary hepatocytes with LPC induced cell death by apoptosis in a concentration-dependent manner. Substituting LPC for PA resulted in caspase-dependent cell death that was accompanied by activating phosphorylation of JNK with c-Jun phosphorylation and an increase in PUMA expression. LPC also induced ER stress as manifest by eIF2α phosphorylation and CAAT/enhancer binding homologous protein (CHOP) induction. LPC cytotoxicity was attenuated by pharmacological inhibition of JNK or glycogen synthase kinase-3 (GSK-3). Similarly, short-hairpin RNA (shRNA)-targeted knockdown of CHOP protected Huh-7 cells against LPC-induced toxicity. The LPC-induced PUMA upregulation was prevented by JNK inhibition or shRNA-targeted knockdown of CHOP. Finally, genetic deficiency of PUMA rendered murine hepatocytes resistant to LPC-induced apoptosis. We concluded that LPC-induced lipoapoptosis is dependent on mechanisms largely indistinguishable from PA. These data suggest that FFA-mediated cytotoxicity is indirect via the generation of the toxic metabolite, LPC.
Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial
Feng, Yang , Cárdenes, Higinia R. , Brell, Joanna M., Cella, David , Flynn, Patrick J. , Ramanathan, Ramesh K., Crane, Christopher H. , Benson, Al B. , Loehrer, Patrick J. , Wagner, Lynne I. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | October 4, 2011 | Volume: 29 | Issue: 31 | Pages: 4105-4112

10.1200/jco.2011.34.8904 | PMID 21969502 Get It

Purpose The purpose of this trial was to evaluate the role of radiation therapy with concurrent gemcitabine (GEM) compared with GEM alone in patients with localized unresectable pancreatic cancer. Patients and Methods Patients with localized unresectable adenocarcinoma of the pancreas were randomly assigned to receive GEM alone (at 1,000 mg/m 2 /wk for weeks 1 to 6, followed by 1 week rest, then for 3 of 4 weeks) or GEM (600 mg/m 2 /wk for weeks 1 to 5, then 4 weeks later 1,000 mg/m 2 for 3 of 4 weeks) plus radiotherapy (starting on day 1, 1.8 Gy/Fx for total of 50.4 Gy). Measurement of quality of life using the Functional Assessment of Cancer Therapy–Hepatobiliary questionnaire was also performed. Results Of 74 patients entered on trial and randomly assigned to receive GEM alone (arm A; n = 37) or GEM plus radiation (arm B; n = 34), patients in arm B had greater incidence of grades 4 and 5 toxicities (41% v 9%), but grades 3 and 4 toxicities combined were similar (77% in A v 79% in B). No statistical differences were seen in quality of life measurements at 6, 15 to 16, and 36 weeks. The primary end point was survival, which was 9.2 months (95% CI, 7.9 to 11.4 months) and 11.1 months (95% CI, 7.6 to 15.5 months) for arms A and B, respectively (one-sided P = .017 by stratified log-rank test). Conclusion This trial demonstrates improved overall survival with the addition of radiation therapy to GEM in patients with localized unresectable pancreatic cancer, with acceptable toxicity.
Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity
Elsawa, Sherine F. , Novak, Anne J. , Ziesmer, Steven C., Almada, Luciana L. , Hodge, Lucy S. , Grote, Deanna M., Fernández-Zapico, Martín E. , Ansell, Stephen M. , Witzig, Thomas E. , Elsawa, Sherine F

Mayo Clinic

Blood | September 16, 2011 | Volume: 118 | Issue: 20 | Pages: 5540-5549

10.1182/blood-2011-04-351742 | PMID 21921047 Get It

AbstractAlthough proinflammatory and chemotactic cytokines can profoundly affect the tumor microenvironment, and many of them have been shown to have therapeutic efficacy in preclinical models, the role of these molecules in Waldenström macroglobulinemia (WM) remains poorly understood. In this study, simultaneous analysis of WM patient sera and bone marrow biopsies identified a set of dysregulated cytokines including CCL5, G-CSF, and soluble IL-2 receptor, that were significantly elevated in WM patients whereas IL-8 and EGF levels were significantly lower in these patients compared with healthy controls. Interestingly, CCL5 levels positively correlated with features of disease aggressiveness such as elevated IgM levels and bone marrow involvement. Functional analysis of tumor microenvironment revealed a functional correlation between CCL5 levels and IL-6 levels, a proinflammatory cytokine with an important role in normal and malignant B-cell biology. Furthermore, CCL5 stimulated IL-6 secretion in WM stromal cells resulting in increased IgM secretion by WM malignant cells via the JAK/STAT signaling pathway. Thus, together these results define a novel signaling network in the WM tumor microenvironment controlling IgM secretion and suggest CCL5 as a potential target for the treatment of this disease.
The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome
D’Souza, Anita , Hayman, Suzanne R. , Mauermann, Michelle L. , Lacy, Martha Q. , Kyle, Robert A. , Kumar, Shaji , Greipp, Philip R., Lust, John A., Russell, Stephen J. , Zeldenrust, Steven R., Dingli, David , Rajkumar, S. Vincent , Dispenzieri, Angela , Buadi, Francis K. , Gertz, Morie A. , Witzig, Thomas E. , Rajkumar, S Vincent , D'Souza, Anita , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Mauermann, Michelle L

Mayo Clinic

Blood | September 1, 2011 | Volume: 118 | Issue: 17 | Pages: 4663-4665

10.1182/blood-2011-06-362392 | PMID 21881050 Get It

Abstract The POEMS syndrome is associated with elevated vascular endothelial growth factor (VEGF) levels. Several studies have compared serum VEGF levels between POEMS patients and other disease entities showing higher serum VEGF in POEMS syndrome; however, it is unknown whether serum levels are reliable and reproducible given variable platelet release of VEGF. We therefore compared plasma levels of VEGF in 29 patients with POEMS syndrome with those of other disorders (n = 76). We demonstrated that plasma VEGF levels are useful in differentiating POEMS from other plasma cell dyscrasias, neuropathic processes, and multisystem illnesses. Plasma VEGF is also useful in monitoring disease activity after treatment and correlates with clinical improvements better than hematologic response.
Upper Extremity and Digital Replantation
Maricevich, Marco , Carlsen, Brian T. , Mardini, Samir , Moran, Steven L.

Mayo Clinic

HAND | August 3, 2011 | Volume: 6 | Issue: 4 | Pages: 356-363

10.1007/s11552-011-9353-5 | PMID 23204960 Get It

Digital replantation has become a well-established technique among reconstructive hand surgeons. Numerous replantation centers around the world have published series with impressive survival rates. The ultimate goal of replantation is the restoration of normal hand or digital function; thus, replantation success is not solely related to the outcome of the microvascular anastomosis, but also to the adequacy of bone, tendon, skin, and nerve repairs. In this manuscript, we review the literature on upper extremity and digital replantation from its historical background to current surgical outcomes, outlining surgical indications and contraindications, and the preoperative, operative, and postoperative management of these patients.
P1‐252: Evaluation of Cognitive Endophenotypes for Association with CLU, CR1 and PICALM LOAD Risk Genes
Pedraza, Otto , Allen, Mariet , Jennette, Kyle J. , Carrasquillo, Minerva M. , Palusak, Ryan, Nguyen, Thuy , Malphrus, Kimberly G., Ivnik, Robert J., Pankratz, Shane, Graff‐Radford, Neill, Roberts, Rosebud O., Petersen, Ronald C. , Younkin, Steven G., Ertekin‐Taner, Nilüfer , Crook, Julia E. , Carrasquillo, Minerva M. , Smith, Glenn E. , Knopman, David S. , Graff‐Radford, Neill

Mayo Clinic

Alzheimer's & Dementia | August 1, 2011 | Volume: 7 | Issue: 4S_Part_6 | Pages: No page available

10.1016/j.jalz.2011.05.532 Get It

P1‐249: Differential Epistatic Interactions with Alternative APOE Alleles in Late‐Onset Alzheimer's Disease
Medway, Christopher, Shi, Hui , Brown, Kristelle, Kalsheker, Noor , Carrasquillo, Minerva M. , Younkin, Steven G. , Morgan, Kevin , Turton, James , Bullock, James M. , Belbin, Olivia , Carrasquillo, Minerva M.

Mayo Clinic

Alzheimer's & Dementia | August 1, 2011 | Volume: 7 | Issue: 4S_Part_6 | Pages: No page available

10.1016/j.jalz.2011.05.529 Get It